Pfizer has signed a research collaboration and licensing agreement with Enodia Therapeutics to discover and develop small-molecule inhibitors of Sec61, the translocon channel that helps synthesize secreted and membrane proteins. Enodia will run discovery and lead optimization across multiple collaboration targets, while Pfizer will take over clinical, manufacturing, regulatory, and commercial activities after the collaboration term ends. Enodia said the deal includes an undisclosed upfront payment and eligibility for research, development and sales milestones plus tiered royalties. The total potential deal value is estimated to exceed $500 million, positioning Sec61 modulation as a continuing high-stakes bet among protein-synthesis pathway innovators. The collaboration builds on Enodia’s platform approach to selectively modulate Sec61 to preserve essential cellular functions, aiming to block disease-driving proteins earlier at synthesis rather than neutralizing them downstream. Enodia also noted prior Sec61-related capability expansion through the purchase of assets from Kezar Life Sciences earlier this year. For biotech investors, the agreement underscores how pharma is crowding into “target-to-translatability” partnerships where the platform owner performs discovery while the pharma partner controls the end-to-end clinical path.